Bageac D, DeBevits JJ, Munbodh R, et al. - Researchers retrospectively examined data of the BECOME trial to evaluate if serial administration of triple-dose (3-dose) gadopentetate dimeglumine would result in the development of T1 signal-to-noise (S/N) changes in the cranial diploic space and if S/N changes correlated with on-study hypophosphatemia. Researchers conducted a signal intensity analysis on the first year's data of the BECOME trial applying 3-dose Gd (14 months, maximum number of doses, 39, mean: 36). The general estimation equation was applied to evaluate the incidence of phosphate abnormalities; correlation of phosphate and S/N change was achieved with type 3 test of fixed effects. The findings revealed that the monthly administration of 3-dose gadopentetate dimeglumine is correlated with development of elevated S/N on T1FS imaging in the cranial diploic space, implying Gd retention in bone. This study's findings demonstrate that MRI could be applied as a non-invasive method of tracking Gd retention in bone, which was more pronounced in patients with normal phosphate levels.